microbes - Box News

The Microbial Dimension of Atopic Dermatitis: Historical Perspectives and Emerging Therapeutic Implications

22 Février 2026, 21:07pm

Publié par Box News

The Microbial Dimension of Atopic Dermatitis: Historical Perspectives and Emerging Therapeutic Implications

Eczema (atopic dermatitis) is best understood today as a condition where three things meet and feed each other: an imperfect skin barrier, an over-reactive immune system, and changes in the microbes that live on the skin. The idea that bacteria play a meaningful role in eczema did not come all at once; it grew out of many observations over decades. The very bacteria most often implicated, staphylococci, were first described in pus by Alexander Ogston in the 1880s, which established that these microbes were common inhabitants and causes of skin infections long before eczema itself was studied in molecular detail. (CDC)

By the 1970s clinicians and microbiologists were noticing a striking pattern: inflamed eczema skin is frequently crowded with a single species, Staphylococcus aureus. In a widely cited paper from the mid-1970s, J. J. Leyden and colleagues showed that S. aureus was present at much higher numbers on eczema lesions than on healthy skin, and follow-up studies in the 1980s confirmed higher carriage and density of the bacterium on both lesional and apparently normal skin of people with atopic dermatitis. Those clinical microbiology findings shifted thinking from “eczema is only an immune or allergic disease” to a model in which microbes help drive flares. (PubMed)

Laboratory work over the next decades explained how the bacteria make things worse. Certain strains of S. aureus produce a mix of molecules — toxins, enzymes and so-called superantigens — that directly damage skin cells, break down the barrier, and powerfully stimulate immune cells. Some toxins punch holes in keratinocytes (the main skin cells), other proteins act like potent signals that make immune cells release inflammatory chemicals, and proteases can expose nerve endings that produce intense itch. Together, these bacterial products turn a vulnerable patch of skin into a site of escalating inflammation. Reviews and experimental studies over the 1990s–2020s summarized and confirmed these mechanisms. (PMC)

At the same time, genetic discoveries clarified why some people are more vulnerable in the first place. A landmark 2006 genetics paper led by Colin N. A. Palmer and collaborators showed that loss-of-function mutations in the gene for filaggrin — a protein that helps form and hydrate the outer layer of skin — are a major risk factor for developing atopic dermatitis. People with filaggrin defects have a weaker barrier, so irritants and microbes get in more easily; that helps explain why the bacterial overgrowth pattern is so common in eczema. The filaggrin discovery shifted research and treatment emphasis toward protecting and repairing the skin barrier, not only suppressing inflammation. (PubMed)

More recently, DNA sequencing and careful sampling have shown that S. aureus doesn’t just passively sit on eczematous skin: particular strains adapt to the inflamed environment, acquire mutations, and express genes that increase their capacity to stick, make toxins, and survive the local conditions. Genomic studies and microevolution analyses in the 2010s and 2020s have mapped those changes and made it clear that the interaction between host (skin + immune system) and bacteria is dynamic — the skin environment shapes the bacteria and the bacteria shape the immune response. (news.mit.edu)

All this history explains why modern treatments take a mixed approach. Restoring the barrier (moisturizers, emollients), calming the over-active immune response when needed (topical steroids or newer targeted drugs), and reducing the harmful activity of bacteria (short courses of antibiotics in some cases, antiseptic washes, or newer anti-virulence strategies) can all be useful — and they work best when combined thoughtfully. One recent innovation, developed by researchers at The University of Hong Kong, is a plant-based moisturizer called Anesinin that aims to “tame” S. aureus by suppressing the bacteria’s toxin production rather than killing the bacteria outright; this is an application of the anti-virulence idea that emerged from the biological studies described above. Early reports are promising but larger clinical trials and peer-reviewed data will be needed to know how broadly and durably such products help. (tech-transfer.med.hku.hk)

In short, eczema is not a simple autoimmune attack but a condition where a weak skin barrier, a sensitized immune system, and sometimes opportunistic bacteria together create a self-reinforcing loop of itch, inflammation and barrier breakdown. The historical arc — from Ogston’s 19th-century description of staphylococci through the 1970s clinical associations, the 2006 filaggrin genetics breakthrough, and the genomics and mechanistic studies of recent years — shows how the field moved from seeing eczema as purely “immune” to seeing it as an ecosystem problem in which bacteria can be important drivers.

(Source : ChatGPT)

Voir les commentaires